finding in many primary and secondary glomerulonephritis. Research suggest TGBM is the consequence of collagen type 4 chains mutations. We aimed to explore the prevalence of thin glomerular membranes (TGBM) in patients with IgA glomerulonephritis (IgA GN). METHODS: 175 patients with IgA nephropathy from our hospital's registry diagnosed between 2007. and 2015. were included in the study. Ultrasound guided kidney biopsy was performed on all patients and samples were analysed using light, immunofluorescent and electron microscopy. We measured glomerular basement membrane thickness and the values were standardised for our nephropathology laboratory: 340636 nm in males and 301644 nm in females. Clinical geneticist analysed family history of patients with TGBM for the presence of possible hereditary kidney diseases and/or microhematuria. Genome sequencing is being done in order to detect COL4a mutations in patients with positive family history. We present one patient with completed analysis. RESULTS: 34 (19.4%) of 175 patients had TGBM described on electron microscopy analysis. Out of those 13 (38.2%) were female with median age 40 (IQR¼17-62). In group of patients with TGBM median serum creatinine levels were 138umol/l (IQR¼64-457umol/l) and daily proteinuria 2.2 grams (IQR¼0.05-10g). Family history of kidney disease and/or microhematuria was positive in 8 (23.5%) patients. We present one of those patients, aged 59 at the time of diagnosis who presented with asymptomatic proteinuria and erythrocyturia. Maximal daily proteinuria was 1.5 grams, serum creatinine was 138 umol/l with eGFR 48ml/min/1.73m 2 . Kidney biopsy revealed IgA GN on immunofluorescent microscopy with mesangial immune deposits on electron microiscopy and thin basement membranes. Patients mother and two brothers had erythrocyturia and one brother had chronic kidney disease. Genome analysis showed patient was hemizygous for COL4a missense mutation c.1871G>A, p.Gly624Asp. CONCLUSIONS: According to research data in up to 20% of IgA GN patients patohistological analysis can reveal presence of concomitant TGBM. It is also important to notice that in IgA GN basement membrane can even have changes described as ,Alport like changes". It is debatable weather TGBM is just patohistological variant in IgA GN or manifestation of separate disease which predisposes to IgA GN. The significance of TGBM as an independant factor in loss of kidney function in IgA GN should be further researched. We suggest importance of detailed family history for erythrocyturia and in selected cases collagen type 4 mutations testing. years] with biopsy proven primary GN and without acute kidney injury, infectious diseases, severe heart failure, respiratory insufficiency, cancer, abnormal thyroid status and treatment with prednisolone more than 10 mg/per day were included in the study. Based on the results of kidney biopsy in 31% of cases a focal segmental glomerulosclerosis was diagnosed, in 28,5% -membranous nephropathy and in 40,5% -IgA-nephropathy. Serum and urine (24-hour collection) creatinine levels were measured in the morning on the day of biopsy by enzymatic method [Uni Cel DxC 800 PRO, «Beckman Coulter», (USA)], serum cystatin C level -by immunoturbidimetric method (Furuno CA-90, Furuno Electric Co., Ltd., Japan). The extent of glomerulosclerosis (GS) was assessed quantitatively as a sum of full and focal sclerotic glomeruli. Tubulo-interstitial fibrosis (TIF) and tubular atrophy (TA) were assessed semi-quantitatively (0-lesions absent; 1-mild focal tubular and interstitial lesions; 2-moderate tubular and interstitial lesions; 3 -diffuse tubular and interstitial lesions). According to the degree of each morphological lesions (GS, TIF or TA) all patients consistently were separated into 2 groups: "light" (GS less than 25% or TIF/TA grade 0 or 1) and "severe" (GS than 25% or TIF/TA grade 2-3). We evaluated specificity, sensitivity and diagnostic accuracy of sCysC regarding to the extent of each morphological lesion (GS/TIF/TA). Diagnostic value of sCysC in GS, TIF, TA prediction was evaluated by ROC-analysis. Statistical analysis was performed with Statistica v.12 (Statsoft Inc., USA) and SPSS v.23 (IBM Corp., USA). RESULTS: sCysC positively correlated with GS (p<0,001; r¼0,53), TIF (p<0,001; r¼0,68) and TA (p<0,001; r¼0,68). sCysC level was significantly higher in patients with "light" GS (p<0,001), TIF (p<0,001) and TA (p<0,001).All patients were separated in 2 groups using sCysC according to the degree of morphological lesions ("light" or "severe"): GS with Sn -60,0%, Sp -84,3%, ACC -73,6%, AUC -0,751, cut-off value -1,82 mg/l;TIF with Sn -76,6%, Sp -74,2%, ACC -75,8%, AUC -0,810, cut-off value -1,23 mg/l;TA with Sn -47,4%, Sp -100,0%, ACC -54,9%, AUC -0,790, cut-off value -1,70 mg/l (Picture 1).
FP194 SERUM CYSTATIN C LEVEL INDICATES EARLY GLOMERULAR AND TUBULAR INTERSTITIAL LESIONS IN PATIENTS WITH PRIMARY GLOMERULONEPHRITIS
CONCLUSIONS: sCysC is a significant marker of various morphological lesions in patient with GN. The sCysC can be used as a predictor of mild degree of glomerular and interstitial sclerosis and tubular atrophy with high diagnostic value. Departments with different practices regarding the use of PAC. Inclusion criteria were a diagnosis of NS with a P-albumin < 30 g/L and a renal biopsy confirming glomerular disease and a follow up of at least three weeks. Exclusion criteria were age < 16 years, diabetic kidney disease, treatment with anticoagulants at onset of NS, and renal replacement therapy. Patients were grouped based whether they received PAC (other than low dose aspirin) or not. All TE and/or bleeding episodes were registered from patient records, and the latter divided into major (blood transfusion required) and minor bleedings (blood transfusion not required). RESULTS: Seventy-nine patients were included in the analysis. Only P-albumin was significantly different between the PAC and non-PAC group (Table, p < 0.001). PAC involved either warfarin with bridging using low-molecular-weight heparin (LMWH), prophylactic dose LMWH, or therapeutic dose LMWH (Table) . Eight and four patients in the PAC group experienced a second and a third relapse, respectively, of NS, which were treated with PAC. In four and three of these patients, respectively, the PAC treatment was different during relapse. None of the 44 patients treated with PAC had a TE; while four patients not receiving PAC experienced a TE (one pulmonary embolism (PE), one PE and deep vein thrombosis, one PE and renal vein thrombosis, and one stroke; P < 0.035 between groups). Two patients receiving PAC in combination with low dose aspirin had a major bleeding episode and tree patients receiving PAC alone had a minor bleeding. This was not statistically different from the non-PAC group, in which two patients had minor bleeding episodes (P ¼ 0.45 between groups). CONCLUSIONS: PAC treatment was associated with a decreased risk of TE in patients with NS. A tendency towards a greater risk of bleeding episodes was identified in patients receiving PAC. Major bleedings was only observed in patients on concomitant anti-platelet treatment.
FP195 PROPHYLATIC ANTICOAGULATION IN NEPHROTIC SYNDROME PREVENTS THROMBOEMBOLIC COMPLICATIONS

FP196 PATTERN OF NON-DIABETIC RENAL DISEASES IN PATIENTS WITH DIABETUS MELLITUS AT STATE RUN TERTIARY CARE CENTER
Umesh Lingaraj CONCLUSIONS: This study emphasizes the pivotal role of the SOCS1/STAT1 axis in regulating inflammation in mesangial proliferative glomerulonephritis. In addition, it demonstrates that SOCS1 is a critical regulator of cellular sensitivity to IFN-c-induced CIITA and MHC class II expression in mesangial cells. The negative feedback between the expression of SOCS1 and inflammation may play an important role in the mesangial proliferative glomerulonephritis.
FP198 SPLEEN TYROSINE KINASE EXPRESSION IN HUMAN NEUTROPHILS IN AAV
Maria Prendecki
INTRODUCTION AND AIMS: Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase which has been shown to play a role in signal transduction in a variety of cell types. Syk phosphorylation has been implicated in activation of neutrophils by ANCA. We have previously demonstrated the presence of Syk in renal biopsy tissue from patients with ANCA associated vasculitis (AAV) and shown that a small molecule Syk inhibitor is an effective treatment in experimental autoimmune vasculitis (EAV), a rat model of AAV. Here, we have investigated the activity of Syk in neutrophils, its role in cytokine production, and expression of Syk in extra-renal sites of vasculitis. METHODS: Neutrophils were isolated from healthy controls and patients with acute AAV using dextran sedimentation and percoll gradient. Intracellular staining for total (T-Syk) and phosphorylated Syk (P-Syk) as two distinct phosphotyrosine residues (319 and 348) was analysed using flow cytometry. 22 AAV samples (14 MPO, 5 PR3, 3 ANCA negative) and 10 healthy controls were includedFor functional studies, neutrophils were primed with TNFa 2ng/ml for 30 minutes and stimulated with 100 mg/ml of IgG containing MPO-ANCA (isolated from the plasma exchange fluid of patients with MPO-AAV) for 4 hours. Cells were incubated with R406, a small molecule Syk inhibitor, or with vehicle for 20 minutes prior to the addition of MPO-ANCA. Control experiments utilised healthy donor IgG in replacement of MPO-ANCA IgG.Immunostaining for T-Syk was carried out on formalin fixed paraffin embedded (FFPE) sections of tissue from patients with extra-renal AAV including ENT, lung and skin disease. RESULTS: There were similar levels of T-Syk present in neutrophils from patients and healthy controls. Levels of P-Syk at both the 319 and 348 residues were increased in AAV (Figure 1a ). The levels of Syk phosphorylation were similar between patients who were MPO-ANCA positive and those who were PR3-ANCA positive. When TNFa primed neutrophils were stimulated with MPO-ANCA there was significant IL-8 release and this was inhibited by R406 in a dose-dependent manner (Figure 1b) . There was also evidence of T-Syk in infiltrating inflammatory cells in non-renal sites of AAV (Figure 2) . CONCLUSIONS: Our results show that Syk is phosphorylated at the 319 and 348 residues to a greater degree in patients with AAV than in healthy controls. Phosphorylation of these sites occurs after Syk activation indicating greater neutrophil Syk activity in patients with AAV. Syk plays a role in cytokine production from neutrophils which
